EP3919619A1 — Multi-targeted single entity conjugates
Assigned to Alnylam Pharmaceuticals Inc · Expires 2021-12-08 · 4y expired
What this patent protects
The present invention relates to a multi-targeted molecule comprising a first double-stranded siRNA molecule and a second double-stranded siRNA molecule, wherein the first siRNA and the second siRNA are covalently linked to each other, and wherein at least one ligand is conjugate…
USPTO Abstract
The present invention relates to a multi-targeted molecule comprising a first double-stranded siRNA molecule and a second double-stranded siRNA molecule, wherein the first siRNA and the second siRNA are covalently linked to each other, and wherein at least one ligand is conjugated with the multi-targeted molecule.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.